全文获取类型
收费全文 | 5401篇 |
免费 | 293篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 25篇 |
儿科学 | 81篇 |
妇产科学 | 38篇 |
基础医学 | 713篇 |
口腔科学 | 125篇 |
临床医学 | 401篇 |
内科学 | 1597篇 |
皮肤病学 | 186篇 |
神经病学 | 314篇 |
特种医学 | 206篇 |
外科学 | 764篇 |
综合类 | 49篇 |
预防医学 | 235篇 |
眼科学 | 46篇 |
药学 | 385篇 |
中国医学 | 4篇 |
肿瘤学 | 549篇 |
出版年
2023年 | 23篇 |
2022年 | 54篇 |
2021年 | 107篇 |
2020年 | 56篇 |
2019年 | 64篇 |
2018年 | 81篇 |
2017年 | 89篇 |
2016年 | 97篇 |
2015年 | 106篇 |
2014年 | 134篇 |
2013年 | 171篇 |
2012年 | 249篇 |
2011年 | 278篇 |
2010年 | 162篇 |
2009年 | 152篇 |
2008年 | 239篇 |
2007年 | 285篇 |
2006年 | 269篇 |
2005年 | 236篇 |
2004年 | 264篇 |
2003年 | 223篇 |
2002年 | 228篇 |
2001年 | 226篇 |
2000年 | 209篇 |
1999年 | 219篇 |
1998年 | 63篇 |
1997年 | 36篇 |
1996年 | 44篇 |
1995年 | 31篇 |
1994年 | 35篇 |
1993年 | 26篇 |
1992年 | 164篇 |
1991年 | 128篇 |
1990年 | 138篇 |
1989年 | 120篇 |
1988年 | 85篇 |
1987年 | 75篇 |
1986年 | 54篇 |
1985年 | 60篇 |
1984年 | 40篇 |
1983年 | 33篇 |
1982年 | 21篇 |
1979年 | 40篇 |
1978年 | 22篇 |
1973年 | 25篇 |
1972年 | 29篇 |
1971年 | 26篇 |
1970年 | 28篇 |
1969年 | 27篇 |
1968年 | 18篇 |
排序方式: 共有5718条查询结果,搜索用时 15 毫秒
81.
In spinocerebellar ataxia type 6 (SCA6), the cerebellum is predominantly affected, but several electrophysiological studies have revealed subclinical disorders other than cerebellar lesions. We conducted statistical analyses by comparing SCA6 patients and age-matched normal controls to asses whether electrophysiological abnormalities are directly associated with SCA6 because late onset of SCA6 may involve senile changes. We performed brain stem auditory evoked potentials (BAEP), visual evoked potentials, somatosensory evoked potentials and nerve conduction studies in 10 SCA6 patients. The BAEP latencies of wave I was prolonged and compound muscle action potentials of peroneal nerve and sensory nerve action potentials of sural nerve reduced in SCA6 patients. Our results suggest an existence of peripheral impairment in the auditory pathway and axonal neuropathy in SCA6. 相似文献
82.
Up-regulation of glial cell line-derived neurotrophic factor (GDNF) following traumatic spinal cord injury 总被引:10,自引:0,他引:10
Satake K Matsuyama Y Kamiya M Kawakami H Iwata H Adachi K Kiuchi K 《Neuroreport》2000,11(17):3877-3881
83.
Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. 总被引:3,自引:0,他引:3
Kenta Yoshiura Takashi Nakaoka Toshihide Nishishita Katsuaki Sato Akifumi Yamamoto Shinji Shimada Toshiaki Saida Yutaka Kawakami Tsuneo A Takahashi Hiroyuki Fukuda Shinobu Imajoh-Ohmi Naoki Oyaizu Naohide Yamashita 《Clinical cancer research》2005,11(22):8201-8207
Tumor-associated antigens are promising candidates as target molecules for immunotherapy and a wide variety of tumor-associated antigens have been discovered through the presence of serum antibodies in cancer patients. We previously conducted dendritic cell therapy on 10 malignant melanoma patients and shrinkage or disappearance of metastatic tumors with massive necrosis occurred in two patients. In this study, we found a 29-kDa protein against which antibody was elicited by dendritic cell therapy in one of the two patients. Matrix-assisted laser desorption ionization-time of flight/mass spectrometry analysis of the protein isolated by two-dimensional electrophoresis combined with Western blots revealed that the 29-kDa protein was carbonic anhydrase II (CA-II). Immunohistochemistry of the tumors and normal tissues showed that CA-II was expressed in the tumor vessel but not in normal vessel endothelium. CA-II expression in tumor endothelium was observed as well in other cancers including esophageal, renal, and lung cancers. In an in vitro angiogenesis model, CA-II expression of normal human vein endothelial cells was significantly up-regulated when cells were cultured in the acidic and hypoxic conditions indicative of a tumor environment. These findings suggest that CA-II is a tumor vessel endothelium-associated antigen in melanoma and other cancers, and elicitation of serum anti-CA-II antibody by dendritic cell therapy may be associated with good clinical outcome including tumor reduction. 相似文献
84.
Yamasaki N Matsumoto K Ohta Y Nishida T Adachi A Nakagawa K Kawakami K 《Kyobu geka. The Japanese journal of thoracic surgery》2000,53(9):791-794
We have experienced thoracoscopic surgery for benign solitary fibrous tumor of the parietal pleura. A 46-year-old woman was admitted to our hospital because of chest abnormal shadow. Under thoracoscopy the tumor that was connected to the parietal pleura with a wide pedicle was completely resected with combined parietal resection of the pleura. Pathological diagnosis was a benign solitary fibrous tumor developed from the connective tissues under the parietal pleura. Thoracoscopic surgery is well indicated for a solitary fibrous tumor and wide excision of the tumor with combined resection of the pleura is important to prevent a local recurrence. 相似文献
85.
K Nakagomi S Sakai H Tanaka N Tomizuka Y Kawakami T Nakajima 《The Journal of antibiotics》1990,43(5):470-476
The planar structures of new eurocidin related compounds, eurocidins D and E, were elucidated from 1H-1H shift correlated 2D NMR spectra and other NMR data. All protons in the molecules were assigned. Eurocidins D and E have novel pentaenic structures of eurocidin family. 相似文献
86.
Nanoarchitectonics integrates nanotechnology with various other fields, with the goal of creating functional material systems from nanoscale units such as atoms, molecules, and nanomaterials. The concept bears strong similarities to the processes and functions seen in biological systems. Therefore, it is natural for materials designed through nanoarchitectonics to truly shine in bio-related applications. In this review, we present an overview of recent work exemplifying how nanoarchitectonics relates to biology and how it is being applied in biomedical research. First, we present nanoscale interactions being studied in basic biology and how they parallel nanoarchitectonics concepts. Then, we overview the state-of-the-art in biomedical applications pursuant to the nanoarchitectonics framework. On this basis, we take a deep dive into a particular building-block material frequently seen in nanoarchitectonics approaches: fullerene. We take a closer look at recent research on fullerene nanoparticles, paying special attention to biomedical applications in biosensing, gene delivery, and radical scavenging. With these subjects, we aim to illustrate the power of nanomaterials and biomimetic nanoarchitectonics when applied to bio-related applications, and we offer some considerations for future perspectives. 相似文献
87.
Kensei Yamaguchi Keiko Minashi Daisuke Sakai Tomohiro Nishina Yasushi Omuro Masahiro Tsuda Shiroh Iwagami Hisato Kawakami Taito Esaki Naotoshi Sugimoto Takashi Oshima Ken Kato Kenji Amagai Hisashi Hosaka Keigo Komine Hisateru Yasui Yuji Negoro Kenji Ishido Takahiro Tsushima Shirong Han Shinichi Shiratori Tomoko Takami Kohei Shitara 《Cancer science》2022,113(8):2814
The KEYNOTE‐659 study evaluated the efficacy and safety of first‐line pembrolizumab plus S‐1 and oxaliplatin (SOX) (cohort 1) or S‐1 and cisplatin (SP) (cohort 2) for advanced gastric/gastroesophageal junction (G/GEJ) cancer in Japan. Herein, we update the results of cohort 1 and describe the results of cohort 2. This open‐label phase IIb study enrolled patients with advanced programmed death‐ligand 1 (PD‐L1)‐positive (combined positive score ≥ 1) human epidermal growth factor receptor 2 (HER2)‐negative G/GEJ adenocarcinoma. The primary end‐point was the objective response rate (ORR). Other end‐points were duration of response (DOR), disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), and safety. One hundred patients were enrolled. In cohorts 1 and 2, median follow‐up time was 16.9 and 17.1 months; ORR (central review), 72.2% and 80.4%; DOR, 10.6 and 9.5 months; DCR (central review), 96.3% and 97.8%; median PFS (central review), 9.4 and 8.3 months; and median OS, 16.9 and 17.1 months, respectively. Treatment‐related adverse events (TRAEs) occurred in all patients, including peripheral sensory neuropathy (94.4%, cohort 1), decreased neutrophil count (82.6%, cohort 2), nausea (59.3% and 60.9% in cohorts 1 and 2), and decreased appetite (61.1% and 60.9% in cohorts 1 and 2). Grade 3 or higher TRAEs were reported by 59.3% (cohort 1) and 78.3% (cohort 2), including decreased platelet count (14.8%, cohort 1) and decreased neutrophil count (52.2%, cohort 2). Pembrolizumab in combination with SOX or SP showed favorable efficacy and safety in patients with PD‐L1‐positive, HER2‐negative G/GEJ adenocarcinoma. 相似文献
88.
89.
Onodera M Kawakami H Kuwatani M Kudo T Haba S Abe Y Kawahata S Eto K Nasu Y Tanaka E Hirano S Asaka M 《Surgical endoscopy》2012,26(6):1710-1717
Background
Endoscopic ultrasound (EUS)-guided drainage is widely used to manage pancreatic pseudocysts. Several studies have reported the use of EUS-guided drainage for pancreatic fistula and stasis of pancreatic juice caused by stricture of the pancreatic duct after pancreatic resection.Methods
At the authors’ hospital, 262 patients underwent surgery involving pancreatic resection from April 2005 to March 2010. In 90 of these patients (34%), a grade B or C postoperative pancreatic fistula developed that required additional treatment. The authors performed EUS-guided transmural drainage (EUS-TD) for six patients (2.1%) with a pancreatic fistula or dilation of the main pancreatic duct visible by EUS. Percutaneous drainage was provided for 18 patients (6.8%). The success rates for EUS-TD and percutaneous drainage were compared in a retrospective analysis.Results
In all six cases, EUS-TD was performed successfully without complications. Five of the six patients were successfully treated with only one trial of EUS-TD. The final technical success rate was 100% for both EUS-TD and percutaneous drainage. Both the short- and long-term clinical success rates for EUS-TD were 100% and those for percutaneous drainage were 61.1 and 83%, respectively. The differences in these rates were not significant (short-term success, P?=?0.091 vs. long-term success, P?=?0.403). However, the time to clinical success was significantly shorter with EUS-TD (5.8?days) than with percutaneous drainage (30.4?days; P?=?0.0013) in the current series.Conclusions
The EUS-TD approach appears to be a safe and technically feasible alternative to percutaneous drainage and may be considered as first-line therapy for pancreatic fistulas visible by EUS. 相似文献90.
Real‐world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus‐infected cirrhosis patients 下载免费PDF全文
Kei Morio Michio Imamura Yoshiiku Kawakami Reona Morio Tomoki Kobayashi Satoe Yokoyama Yuko Nagaoki Tomokazu Kawaoka Masataka Tsuge Akira Hiramatsu Grace Naswa Makokha C Nelson Hayes Hiroshi Aikata Daiki Miki Hidenori Ochi Yoji Honda Nami Mori Shintaro Takaki Keiji Tsuji Kazuaki Chayama 《Journal of gastroenterology and hepatology》2017,32(3):645-650